GlassScriptPhysician profile
Dana Marshall
NPI 1831413855
$7,589.52
in general payments reported to CMS, 2019-2025
27 companies · $3,350 in 2025
The $3,350 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $234 · 2021: $592 · 2022: $958 · 2023: $608 · 2024: $1,058 · 2025: $3,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248 · Consulting Fee: $1,650 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.83 |
| Consulting Fee | $1,650.00 |
| Education | $117.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,335.54 | 2025 | Tremfya |
| Abbvie INC. | $1,878.45 | 2019-2025 | |
| Genzyme Corporation | $596.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.69 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $262.23 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $254.76 | 2019-2025 | Bimzelx |
| Amgen INC. | $215.42 | 2019-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $214.76 | 2022-2025 | Dupixent |
| Pfizer INC. | $203.93 | 2019-2023 | |
| Journey Medical Corporation | $170.73 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $143.97 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $136.48 | 2021-2024 | Absorica Ld, Winlevi |
| Incyte Corporation | $136.19 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $122.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.41 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $77.00 | 2025 | Daxxify |
| Allergan, INC. | $60.55 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.54 | 2021-2022 | |
| Almirall LLC | $50.50 | 2019-2023 | Seysara |
| Mylan Pharmaceuticals INC. | $40.56 | 2019 | |
| Celgene Corporation | $33.52 | 2019 | |
| Merz North America, INC. | $29.72 | 2019 | |
| Organon LLC | $24.75 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $21.19 | 2019 | |
| Aclaris Therapeutics, INC. | $18.63 | 2019 | |
| Merck Sharp & Dohme LLC | $17.69 | 2019 | |
| Lilly USA, LLC | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.